Sarah Meibusch

Sarah Meibusch has held various positions in the biotechnology industry since 2009. Sarah began their career as a Principal at BearTrap Solutions Pty Ltd, a consulting company, in 2009. In 2012, they became a Member of the Board of Advisors and Deputy Director at Queensland Alliance for Agriculture and Food Innovation (QAAFI). In 2017, they joined OneVentures as a Partner and Investment Manager, and in 2019 they became a Non-Executive Director at Kira Biotech Pty Ltd and Life Sciences Queensland Limited. Additionally, they have held Board Observer roles at Blade Therapeutics, Vaxxas, and Paragen Bio since 2019. In 2021, they joined Axial Therapeutics, Inc. as a Non-Executive Director.

Sarah Meibusch's education history includes completing a Bachelor of Agricultural Science from The University of Queensland in 1998, followed by a Masters from Cornell University in 2001 in Commercialization of Innovation. In 2007, they attended Harvard Business School for an Executive Education Program in Negotiation and Competitive Decision Making. In 2015, they completed the Australian Company Directors Course (GAICD) at the Australian Institute of Company Directors.